ES2196153T3 - Vacunas de conjugados de polisacaridos menmingococicos modificados. - Google Patents

Vacunas de conjugados de polisacaridos menmingococicos modificados.

Info

Publication number
ES2196153T3
ES2196153T3 ES96917303T ES96917303T ES2196153T3 ES 2196153 T3 ES2196153 T3 ES 2196153T3 ES 96917303 T ES96917303 T ES 96917303T ES 96917303 T ES96917303 T ES 96917303T ES 2196153 T3 ES2196153 T3 ES 2196153T3
Authority
ES
Spain
Prior art keywords
modified
polisacarids
polysacarids
menmingococices
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96917303T
Other languages
English (en)
Inventor
Harold J Jennings
Robert Pon
Michele Lussier
Francis Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Application granted granted Critical
Publication of ES2196153T3 publication Critical patent/ES2196153T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Abstract

LA INVENCION SE REFIERE A POLISACARIDOS DEL GRUPO B QUIMICAMENTE MODIFICADOS DE NEISSERIA MENINGITIDIS. LA INVENCION PROPORCIONA ASIMISMO VACUNAS EN LAS QUE LOS CORRESPONDIENTES POLISACARIDOS MODIFICADOS ESTAN CONJUGADOS A UNA PROTEINA VEHICULO Y SIMILARES. MAS ESPECIFICAMENTE, LA PRESENTE INVENCION PROPORCIONA NUEVOS POLISACARIDOS DERIVADOS DE N MENINGOCOCALES DEL GRUPO B, NUEVOS CONJUGADOS DE POLISACARIDOS DERIVADOS DE N COMPOSICIONES FARMACEUTICAS QUE CONTIENEN MOLECULAS CONJUGADAS DE FRAGMENTOS DE POLISACARIDOS DERIVADOS DE N DOS MENINGOCOCALES DEL GRUPO B UNIDOS COVALENTEMENTE A PROTEINAS, Y EL USO DE ESTAS COMPOSICIONES COMO VACUNAS.
ES96917303T 1995-06-07 1996-06-07 Vacunas de conjugados de polisacaridos menmingococicos modificados. Expired - Lifetime ES2196153T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/484,569 US5811102A (en) 1995-06-07 1995-06-07 Modified meningococcal polysaccharide conjugate vaccines

Publications (1)

Publication Number Publication Date
ES2196153T3 true ES2196153T3 (es) 2003-12-16

Family

ID=23924694

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96917303T Expired - Lifetime ES2196153T3 (es) 1995-06-07 1996-06-07 Vacunas de conjugados de polisacaridos menmingococicos modificados.

Country Status (18)

Country Link
US (4) US5811102A (es)
EP (1) EP0831898B1 (es)
JP (2) JP4171068B2 (es)
KR (1) KR100452475B1 (es)
CN (1) CN1163270C (es)
AT (1) ATE238064T1 (es)
AU (1) AU706053B2 (es)
BR (1) BR9609229A (es)
CA (1) CA2223567C (es)
CZ (1) CZ391497A3 (es)
DE (1) DE69627652T2 (es)
ES (1) ES2196153T3 (es)
HU (1) HU224972B1 (es)
IL (3) IL118604A0 (es)
NO (1) NO321705B1 (es)
PL (1) PL184125B1 (es)
WO (1) WO1996040239A1 (es)
ZA (1) ZA964823B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
EP0939647B2 (en) * 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
EP2226336B1 (en) * 1997-12-23 2016-10-19 Pfizer Ireland Pharmaceuticals Bacterial capsular polysaccharide for use as vaccines or for linking to proteins in conjugate vaccines
AU771330B2 (en) * 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
CA2279134A1 (en) * 1999-07-29 2001-01-29 Tianmin Liu Novel strategy for carbohydrate-based therapeutic vaccines
EP1307221A2 (en) * 2000-07-28 2003-05-07 National Research Council of Canada Modified sialic acid vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
DE60235155D1 (de) * 2001-04-17 2010-03-11 Childrens Hosp Oak Res Inst Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
EP2851088A1 (en) * 2003-06-23 2015-03-25 Baxter International Inc. Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof
EP1784428A2 (en) * 2004-06-23 2007-05-16 Children's Hospital & Research Center at Oakland Polysaccharide derivatives and uses in induction of an immune response
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP1863536A4 (en) * 2005-03-14 2011-07-20 Univ Alberta VACCINE BASED ON SYNTHETIC OLIGOSACCHARIDES AGAINST CANDIDA ALBICANS
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TR201807355T4 (tr) * 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Meningokokkal konjugatlarla immünizasyon rejimleri.
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
ES2387582T3 (es) 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio
EP2170391B1 (en) * 2007-06-20 2017-01-18 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
EP2383035A4 (en) 2008-12-03 2017-11-22 Kaneka Corporation Formyl group-containing porous support, adsorbent using same, method for producing same, and method for producing the adsorbent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5034516A (en) * 1987-08-04 1991-07-23 University Of Ottawa Synthetic antigens of sialic acid and derivatives thereof
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
JP2637845B2 (ja) * 1989-12-14 1997-08-06 ナシヨナル・リサーチ・カウンシル・カナダ 修飾メニンゴコツクス多糖複合ワクチン
FI903414A (fi) 1990-07-06 1992-01-07 Kansanterveyslaitos Produktion av proteiner i grampositiva bakterier.
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Also Published As

Publication number Publication date
US6350449B1 (en) 2002-02-26
KR19990022748A (ko) 1999-03-25
EP0831898B1 (en) 2003-04-23
IL147121A (en) 2009-07-20
CN1163270C (zh) 2004-08-25
HUP9802664A3 (en) 1999-12-28
US6596283B2 (en) 2003-07-22
PL184125B1 (pl) 2002-09-30
PL323862A1 (en) 1998-04-27
ATE238064T1 (de) 2003-05-15
US5969130A (en) 1999-10-19
IL147121A0 (en) 2002-08-14
JP2008285675A (ja) 2008-11-27
HUP9802664A2 (hu) 1999-02-01
JPH11506491A (ja) 1999-06-08
KR100452475B1 (ko) 2004-12-30
CN1187136A (zh) 1998-07-08
US20020031511A1 (en) 2002-03-14
AU706053B2 (en) 1999-06-10
NO975547D0 (no) 1997-12-02
HU224972B1 (en) 2006-04-28
US5811102A (en) 1998-09-22
DE69627652T2 (de) 2004-02-12
DE69627652D1 (de) 2003-05-28
JP4171068B2 (ja) 2008-10-22
CZ391497A3 (cs) 1998-05-13
IL118604A0 (en) 1996-10-16
NO321705B1 (no) 2006-06-26
ZA964823B (en) 1997-08-01
CA2223567A1 (en) 1996-12-19
WO1996040239A1 (en) 1996-12-19
NO975547L (no) 1998-02-09
BR9609229A (pt) 1999-07-27
CA2223567C (en) 2009-02-03
AU5993796A (en) 1996-12-30
EP0831898A1 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
ES2196153T3 (es) Vacunas de conjugados de polisacaridos menmingococicos modificados.
CL2020002024A1 (es) Moduladores de calpaínas y usos terapeuticos de los mismos. (divisional solicitud 201900793)
PE20070499A1 (es) Composicion inmunogenica
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
CL2021000901A1 (es) Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo
NO20002786D0 (no) Adamantanderivater
SV2003000704A (es) Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona pc11075/700018/bb
HUP0002322A2 (hu) Multivalens vakcinakészítmény kevert hordozóval
ATE334676T1 (de) Photo-empfindlichkeit-erhöhende conjugate zur targeting von pathogene
BRPI0417341A (pt) fator ix glicopeguilado
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ATE336229T1 (de) Zusammensetzung auf der basis polymerer mizellen
DE3786000T3 (de) Conjugate dichter Sterne.
CY1114062T1 (el) Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης
DK1545613T3 (da) Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
BR9815388A (pt) Polissacarìdeos formadores de iminas, sua preparação e seu uso como adjuvantes e imunoestimulantes
WO2019136180A3 (en) Heteroduplex nucleic acid molecules and uses thereof
AR026593A1 (es) Formulaciones para agentes farmaceuticos ionizables como acidos libres o bases libres
ATE521366T1 (de) Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
CY1106128T1 (el) Μεσο χορηγησης δοσης για συσκευη εγχυσης